Prof. Yair Herishanu

Director; The research laboratory for CLL cell biology; Hematology Division


Education

1989-1995    Medical School, Ben-Gurion University, Beer-Sheva, Israel
1997-1998    Residency in Internal Medicine, Rabin Medical Center
1998-2001    Residency in Internal Medicine, Meir Medical Center
2001-2004    Residency in Hematology, Department of Hematology, Tel Aviv  Medical Center

2004-2006    Senior Hematologist, Hematology Department, Tel Aviv  Medical Center
2006-2008    Research Fellow at the Hematology Branch in NHLBI/National Institute of Health (NIH), Bethesda, Maryland, USA

Clinical experience

1997-1998 Residency in Internal Medicine, Rabin Medical Center
1998-2001 Residency in Internal Medicine, Meir Medical Center
2001-2004 Residency in Hematology, Department of Hematology, Tel Aviv  Medical Center 2004-2006 Senior Hematologist, Hematology Department, Tel Aviv  Medical Center

 

Prizes and achivements

2004  Young Investigator Research Prize of the Medicine Division of Tel-Aviv Sourasky Medical Center
2006 Prize of Clinical Excellence from Tel Aviv Sourasky Medical Center    2006 Award from Anti-Cancer Israeli Organization
2006 Israel Medical Association Grant in honor of Prof. Baruch Gali
2007 Recipient of a Harry and Bella Wexner Fellowship for Medical Education and Research of the Legacy Heritage Fund, American Physician Fellowship for Medicine in Israel
2007 Recipient of Klitzberg Oncology Award, American Physician Fellowship for Medicine in Israel
2008 Recipient of a Travel Award from American Society of Hematology
2009 Grant Award of Excellence from Tel Aviv Sourasky Medical Center
2010 Recipient of Weizmann Institute-TASMC collaboration grant
2011  Recipient of Israeli Science Foundation grant (Morasha project)

Union membership

Israeli Hematology Association
American Hematology Association

Areas of interest

My main clinical and research interests are in the field of chronic lymphocytic leukemia. I lead the CLL clinic and I am engaged in basic research that focuses on the interactions of CLL cells with the tissue microenvironment. Recently, we were able to establish the in-vivo regulation of CLL cells at transcriptional level during their interaction with the tissue microenvironment. Our data revealed novel genes which are likely to play a role in CLL biology and highlight the importance of the NF-kB pathway and the B-cell receptor as potential therapeutic targets in order to overcome the supporting action of the tissue microenvironment. Currently we work to elucidate the functional role of these novel genes in the pathogenesis of CLL. Our research may enable the development of novel biological therapeutic agents for CLL.